TG Therapeutics Inc chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share 0.04
Dividend & YieldN/A$ (N/A)
Beta 2.11
Market capitalization 1.18B
Operating cash flow -239.21M
ESG Scores unknown

Company description

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.

Sector: Healthcare - Industry: Biotechnology

Financial Ratios
Quick Ratio5.06
Working Capital-1.31
Return On Equity-1.47
Debt To Equity0.28
Fixed Asset Ratio2.21
Fixed Interest Cover-61.15

Financial data

Financial Statements

Cashflow Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Change To Liabilities 10.8M -4.95M 11.48M 15.84M
Total Cashflows From Investing Activities 1.18M -718k -24.51M -332k
Net Borrowings 29.99M 29.99M 40M 40M
Total Cash From Financing Activities 113.64M 204.21M 679.83M 41.42M
Change To Operating Activities 16.73M 30.14M -31.24M -26.67M
Issuance Of Stock 113.64M 175.02M 679.83M 2.44M
Net Income -173.48M -172.87M -279.38M -348.1M
Change In Cash -14.11M 70.69M 440.81M -254.55M
Effect Of Exchange Rate
Total Cash From Operating Activities -128.93M -132.81M -214.51M -295.63M
Depreciation 88k 100k 158k 282k
Change To Account Receivables -1.39M -1.39M -1.39M -1.39M
Other Cashflows From Financing Activities -795k -795k -1.02M -1.02M
Change To Netincome 16.8M 13.82M 83.33M 63.11M
Capital Expenditures -90k -131k -357k -401k

Income Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Research Development 159.39M 154.18M 165.9M 222.58M
Income Before Tax -173.48M -172.87M -279.38M -348.1M
Net Income -173.48M -172.87M -279.38M -348.1M
Selling General Administrative 15.16M 15.03M 107.85M 128.09M
Gross Profit 152k 152k 152k 5.9M
Ebit -174.4M -169.06M -273.59M -344.77M
Operating Income -174.4M -169.06M -273.59M -344.77M
Interest Expense -877k -5.29M -6.33M -5.64M
Income Tax Expense
Total Revenue 152k 152k 152k 6.69M
Cost Of Revenue 790k
Total Other Income ExpenseNet 918k -3.82M -5.79M -3.33M
Net Income From Continuing Ops -173.48M -172.87M -279.38M -348.1M
Net Income Applicable To Common Shares -173.48M -172.87M -279.38M -348.1M

Balance Sheet Statement 2018-12-31 2019-12-31 2020-12-31 2021-12-31
Total Liabilities 59.58M 124.4M 106.29M 142.48M
Total Stockholder Equity 24.04M 38.62M 519.35M 237.15M
Other Current Liabilities 152k 48.8M 17.3M 1.55M
Total Assets 83.62M 163.01M 625.64M 379.63M
Common Stock 84k 109k 141k 143k
Other Current Assets 10.13M 8.72M 6.31M 14.81M
Retained Earnings -528.35M -701.22M -980.6M -1.33B
Treasury Stock -234k -234k -234k -234k
Cash 41.96M 112.64M 553.44M 298.89M
Total Current Liabilities 38.85M 84.45M 87.55M 65.38M
Other Stockholder Equity
Property, Plant, and Equipment 251k 9.68M 9.79M 9.23M
Total Current Assets 79.03M 149.15M 611.74M 330.96M
Net Tangible Assets 23.24M 37.82M 518.55M 236.35M
Net Receivables 1.39M
Accounts Payable 36.38M 30.04M 37.01M 50.89M


Insider Transactions

Here are the insider transactions of stock shares related to TG Therapeutics Inc:

Filer Name Transaction Text Ownership Date Filer Relation Shares
CHARNEY LAURENCE NEILStock Award(Grant) at price 0.00 per share.D2022-07-20Director43.73k
POWER SEAN AStock Award(Grant) at price 0.00 per share.D2022-07-20Chief Financial Officer75k
ECHELARD YANNStock Award(Grant) at price 0.00 per share.D2022-07-20Director43.73k
HOBERMAN KENNETHStock Award(Grant) at price 0.00 per share.D2022-07-20Director43.73k
HUME DANIELStock Award(Grant) at price 0.00 per share.D2022-07-20Director43.73k
LONIAL SAGARStock Award(Grant) at price 0.00 per share.D2022-07-20Director43.73k
WEISS MICHAEL SSale at price 18.31 - 19.20 per share.D2022-01-05Chief Executive Officer68.22k
POWER SEAN ASale at price 18.31 - 19.20 per share.D2022-01-05Chief Financial Officer84.97k
WEISS MICHAEL SStock Award(Grant) at price 0.00 per share.D2021-12-29Chief Executive Officer56.39k
WEISS MICHAEL SStock Gift at price 0.00 per share.D2021-12-16Chief Executive Officer712k
WEISS MICHAEL SStock Award(Grant) at price 0.00 per share.D2021-06-18Chief Executive Officer1.08M
CHARNEY LAURENCE NEILStock Award(Grant) at price 0.00 per share.D2021-06-18Director60k
POWER SEAN AStock Award(Grant) at price 0.00 per share.D2021-06-18Chief Financial Officer25k
ECHELARD YANNStock Award(Grant) at price 0.00 per share.D2021-06-18Director20k
HOBERMAN KENNETHStock Award(Grant) at price 0.00 per share.D2021-06-18Director20k
HUME DANIELStock Award(Grant) at price 0.00 per share.D2021-06-18Director20k
LONIAL SAGARStock Award(Grant) at price 0.00 per share.D2021-06-18Director20k
POWER SEAN AStock Award(Grant) at price 0.00 per share.D2020-12-30Chief Financial Officer20k
WEISS MICHAEL SStock Gift at price 0.00 per share.D/I2020-12-28Chief Executive Officer1.37M
POWER SEAN AStock Gift at price 0.00 per share.D2020-12-21Chief Financial Officer132k
ECHELARD YANNSale at price 40.05 per share.D2020-12-10Director30k

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to TG Therapeutics Inc. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on TG Therapeutics Inc

Here is the result of two systematic investment strategies applied to TG Therapeutics Inc. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on TG Therapeutics Inc

The following chart shows the equity curve of the two systematic investment strategies applied to TG Therapeutics Inc:

TG Therapeutics Inc automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 149.77% on the backtest period.

Performance at glance

Performance

149.77 %

Latent gain

3316.84 $

Invested capital

2214.68 $

Annualized return

36.18 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on TG Therapeutics Inc

This is the result of two momentum investment strategies applied to TG Therapeutics Inc. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on TG Therapeutics Inc

The following chart shows all the entries opened by the momentum investment system on TG Therapeutics Inc:

TG Therapeutics Inc momentum entries
  • The first momentum investment strategy would give 198.82% of return on TG Therapeutics Inc. That represents 8922.84$ of latent gain with 4487.88$ of employed capital.
  • The second momentum investment strategy would give 187.12% of return on TG Therapeutics Inc. That represents 6015.25$ of latent gain with 3214.67$ of employed capital.
Performance at glance (1Q Momentum)

Performance

198.82 %

Latent gain

8922.84 $

Invested capital

4487.88 $

Annualized return

66.17 %
Performance at glance (2Q Momentum)

Performance

187.12 %

Latent gain

6015.25 $

Invested capital

3214.67 $

Annualized return

51.13 %

Momentum equity curve on TG Therapeutics Inc

The following chart shows the equity curve of the two momentum strategies applied to TG Therapeutics Inc:

TG Therapeutics Inc momentum equity

Note: the dividends potentially given by TG Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on TG Therapeutics Inc

The following chart shows the employed capital evolution of the two momentum strategies on TG Therapeutics Inc since the beginning:

TG Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on TG Therapeutics Inc

Buy the dip entry openings on TG Therapeutics Inc

TG Therapeutics Inc

The performance achieved by the robo-advisor on TG Therapeutics Inc is 141.61%. That represents 1432.54$ of latent gain with 1011.62$ of employed capital. The following chart shows TG Therapeutics Inc stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of TG Therapeutics Inc, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

141.61 %

Latent gain

1432.54 $

Invested capital

1011.62 $

Annualized return

66.17 %

Equity curve of the strategy applied to TG Therapeutics Inc

The following chart shows the result of the investment strategy applied to TG Therapeutics Inc:

TG Therapeutics Inc

Note: the dividends potentially given by TG Therapeutics Inc are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on TG Therapeutics Inc

The following chart shows the employed capital evolution since the beginning of the investment strategy on TG Therapeutics Inc:

TG Therapeutics Inc

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on TG Therapeutics Inc

In this section, I will compare the three previous investment strategies applied to TG Therapeutics Inc.

Equity curve comparison on TG Therapeutics Inc

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

TG Therapeutics Inc investment strategy comparison

Employed capital comparison on TG Therapeutics Inc

TG Therapeutics Inc investment comparison

Performance comparison on TG Therapeutics Inc

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 149.77% 3316.84$ 2214.68$ 36.18%
Momentum 1 quarter 198.82% 8922.84$ 4487.88$ 50.98%
Momentum 2 quarters 187.12% 6015.25$ 3214.67$ 51.13%
Non-directional 141.61% 1432.54$ 1011.62$ 66.17%
Annualized return comparison

Automatic investment

36.18 %

Momentum 1Q

51.13 %

Momentum 2Q

51.13 %

Non-directional

66.17 %

Correlated stocks

Here are the most positively and negatively correlated stocks with TG Therapeutics Inc:

Positive correlations

Most correlated stocks this year

  • TG Therapeutics Inc

  • Most correlated stocks last 3 months

  • B. Riley Financial Inc
  • TG Therapeutics Inc
  • CAPITAL VC

  • Negative correlation

    Most negatively correlated stocks this year


    Most negatively correlated stocks last 3 months

  • SYNCONA LIMITED ORD NPV
  • SPDR(R) S&P(R) PHARMACEUTICALS ETF

  • Note: The algorithm computes the probability of correlation between TG Therapeutics Inc and the other stocks. There may be false positives or some missing correlated stocks. If the price of TG Therapeutics Inc does not vary for 36 weeks, the correlation calculation result will be wrong.


    Company information

    Company name TG Therapeutics Inc
    Country United States
    City New York
    Address 2 Gansevoort Street
    Phone 212 554 4484
    Website www.tgtherapeutics.com
    FullTime employees 186
    Industry Biotechnology
    Sector Healthcare
    Exchange XNAS
    Ticker TGTX
    Market www.nasdaq.com

    TG Therapeutics Inc ESG Scores

    Environment scores

    Environment ESG Factors Scores
    Environment Score 0
    Peer Environment Performance unknown
    Environment Percentile unknown
    Palm Oil unknown
    Nuclear unknown
    Fur Leather unknown
    GMO unknown
    Coal unknown
    Pesticides unknown
    Animal Testing unknown

    Social scores

    Social ESG Factors Scores
    Social Score 0
    Peer Social Performance unknown
    Social Percentile unknown
    Highest Controversy unknown
    Peer Highest Controversy Performance unknown
    Adult unknown
    Gambling unknown
    Alcoholic unknown
    Tobacco unknown
    Catholic unknown
    Controversial Weapons unknown
    Small Arms unknown
    Military Contract unknown
    Peer Count unknown

    Related Controversy:


    Governance scores

    Governance ESG Factors Scores
    Governance Score 0
    Peer Governance Performance unknown
    Governance Percentile unknown

    ESG at glance
    Total ESG Scores: unknown
    Environment Score: 0
    Social Score: 0
    Governance Score: 0

    ESG Performance: unknown

    Peer Group: unknown

    Peer Esg Score Performance: unknown

    Rating Year: unknown

    Rating Month: unknown

    Max Age: unknown

    Percentile: unknown